Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: Current guidelines for the optimal ablation strategy for persistent atrial fibrillation (PerAF) remain unclear. While our previous RCT confirmed the favourable prognosis of aggressive ablation, real-world evidence is still lacking.
Methods And Results: Among 4833 PerAF patients undergoing catheter ablation at 10 centres, two groups were defined: regular ablation (PVI-only or PVI plus anatomical ablation) and aggressive ablation (anatomical plus electrogram-guided ablation), with 1560 patients each after propensity score (PS) matching. The primary endpoint was 12-month AF/atrial tachycardia (AT) recurrence-free survival off anti-arrhythmic drugs after a single procedure. Additional PS matching was performed within the regular group between PVI-only and anatomical ablation (n = 455 each). Furthermore, anatomical ablation from the regular group was independently matched with aggressive ablation (n = 1362 each). At 12 months, the aggressive group showed superior AF/AT-free survival (66.2% vs. 59.3%, P < 0.001; HR 0.745), similar AT recurrence (12.0% vs. 11.3%, P = 0.539), and significantly higher procedural AF termination (67.0% vs. 21.0%, P < 0.001) than regular group. Moreover, patients with AF termination had improved AF/AT-free survival (72.3% vs. 55.2%, P < 0.001). Safety endpoints did not differ significantly between the two groups. Both the ablation outcomes and AF termination rate showed increasing trends with the extent of ablation aggressiveness but declined with extremely aggressive ablation. After additional PS matching, within the regular group, no statistical differences were observed though AF/AT-free survival in the anatomical group was slightly higher than the PVI-only group (60.7% vs. 55.6%, P = 0.122); while aggressive ablation showed improved AF/AT-free survival compared to anatomical ablation alone from regular group (67.5% vs. 59.9%, P < 0.001).
Conclusion: Aggressive ablation achieved more favourable outcomes than regular ablation, and moderately aggressive ablation may be associated with better clinical outcomes. AF termination is a reliable ablation endpoint.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920505 | PMC |
| http://dx.doi.org/10.1093/europace/euaf045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity.
J Pharmacol Exp Ther
August 2025
Animal Cancer Care and Research Program, University of Minnesota, St Paul, Minnesota; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Center for Immunology
We evaluated the antitumor effects of remodeling the MC17 mouse sarcoma microenvironment (SME) by targeting urokinase-type plasminogen activator receptor (uPAR)- and epidermal growth factor receptor (EGFR)-expressing cells. Specifically, we used eBAT (a bispecific ligand-targeted toxin directed to EGFR and uPAR), and its mouse counterpart, meBAT, to ablate uPAR- and/or EGFR-expressing cells. We chose the MC17 model because the cells are resistant to eBAT, allowing us to exclusively evaluate the role of uPAR- and EGFR-expressing cells in the SME.
View Article and Find Full Text PDFCT-based deep learning radiomics model for predicting proliferative hepatocellular carcinoma: application in transarterial chemoembolization and radiofrequency ablation.
BMC Med Imaging
September 2025
Department of Radiology, Tianjin First Central Hospital, Tianjin Institute of Imaging Medicine, School of Medicine, Nankai University, 24 Fukang Road, Nankai District, Tianjin, 300192, China.
Objectives: Proliferative hepatocellular carcinoma (HCC) is an aggressive tumor with varying prognosis depending on the different disease stages and subsequent treatment. This study aims to develop and validate a deep learning radiomics (DLR) model based on contrast-enhanced CT to predict proliferative HCC and to implement risk prediction in patients treated with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA).
Materials And Methods: 312 patients (mean age, 58 years ± 10 [SD]; 261 men and 51 women) with HCC undergoing surgery at two medical centers were included, who were divided into a training set ( = 182), an internal test set ( = 46) and an external test set ( = 84).
A preliminary comparative study of microwave ablation for cervical lymph node metastases originating from papillary thyroid carcinoma vs. non-papillary thyroid carcinoma.
Int J Hyperthermia
December 2025
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Purpose: This study aims to evaluate the feasibility, efficacy, and safety of microwave ablation (MWA) for cervical lymph node metastasis (CLNM) originating from papillary thyroid carcinoma (PTC) versus non-papillary thyroid carcinoma (non-PTC).
Methods: In this retrospective study, 262 patients with CLNM treated by MWA between July 2016 and May 2024 were included. Comparative study based on propensity score matching (PSM) between the PTC and non-PTC groups was carried out.
A bispecific antibody-drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia.
MAbs
December 2025
BiVictriX Therapeutics Ltd, Cheshire, UK.
Acute myeloid leukemia (AML) is a heterogeneous malignancy with poor clinical outcome. Aberrant expression of CD7 in AML patients is linked to shorter overall survival and lack of response to standard of care therapy. CD33/CD7 co-expression on leukemic blasts occurs in approximately one-third of AML patients and is known to be absent in normal myeloid cells.
View Article and Find Full Text PDFClinical and Imaging-Based Prognostic Models for Recurrence and Local Tumor Progression Following Thermal Ablation of Hepatocellular Carcinoma: A Systematic Review.
Cancers (Basel)
August 2025
Department of Radiology, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands.
Early detection of patients at high risk for recurrence or local tumor progression (LTP) following thermal ablation of hepatocellular carcinoma (HCC) is essential for treatment selection and individualized follow-up. This systematic review aims to assess and compare the performance of prognostic models predicting recurrence or LTP in patients with HCC treated with thermal ablation. PubMed, Web of Science, Cochrane, and Embase were searched for studies developing models to predict recurrence after thermal ablation in treatment-naïve HCC patients, using imaging and clinical data with reported test set performance.
View Article and Find Full Text PDF